scispace - formally typeset
Open AccessJournal ArticleDOI

Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD.

Reads0
Chats0
TLDR
In the context of raised Ca and P, vascular calcification is a modifiable, cell-mediated process regulated by vesicle release, and perturbation of the production or function of these inhibitors would lead to accelerated vascular calcifying.
Abstract
Patients with ESRD have a high circulating calcium (Ca) phosphate (P) product and develop extensive vascular calcification that may contribute to their high cardiovascular morbidity. However, the cellular mechanisms underlying vas- cular calcification in this context are poorly understood. In an in vitro model, elevated Ca or P induced human vascular smooth muscle cell (VSMC) calcification independently and synergistically, a process that was potently inhibited by serum. Calcification was initiated by release from living VSMC of membrane-bound matrix vesicles (MV) and also by apoptotic bodies from dying cells. Vesicles released by VSMC after prolonged exposure to Ca and P contained preformed basic calcium phosphate and calcified extensively. However, vesi- cles released in the presence of serum did not contain basic calcium phosphate, co-purified with the mineralization inhib- itor fetuin-A and calcified minimally. Importantly, MV re- leased under normal physiologic conditions did not calcify, and VSMC were also able to inhibit the spontaneous precipitation of Ca and P in solution. The potent mineralization inhibitor matrix Gla protein was found to be present in MV, and pre- treatment of VSMC with warfarin markedly enhanced vesicle calcification. These data suggest that in the context of raised Ca and P, vascular calcification is a modifiable, cell-mediated process regulated by vesicle release. These vesicles contain mineralization inhibitors derived from VSMC and serum, and perturbation of the production or function of these inhibitors would lead to accelerated vascular calcification.

read more

Citations
More filters
Journal ArticleDOI

Chronic Kidney Disease Effects on the Cardiovascular System

TL;DR: Prevention and treatment of cardiovascular disease are major considerations in the management of individuals with chronic kidney disease, which may lead to increased morbidity and mortality as a result of cardiovascular events.
Journal ArticleDOI

Vascular Calcification Pathobiology of a Multifaceted Disease

TL;DR: Clinically, vascular calcification is now accepted as a valuable predictor of coronary heart disease, and, conversely, many treatments for cardiovascular disease such as statins, antioxidants, hormone replacement therapy, ACE inhibitors, fish oils, and calcium channel blockers may affect bone health.
Journal ArticleDOI

Vascular Calcification Pathobiological Mechanisms and Clinical Implications

TL;DR: It now appears that vascular calcification is a consequence of tightly regulated processes that culminate in organized extracellular matrix deposition by osteoblast-like cells.
Journal ArticleDOI

Arterial Calcification in Chronic Kidney Disease: Key Roles for Calcium and Phosphate

TL;DR: A major role is suggested for elevated P in promoting osteogenic/chondrogenic differentiation of VSMC, whereas elevated Ca has a predominant role in promoting VSMC apoptosis and vesicle release.
Journal ArticleDOI

Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients.

TL;DR: Baseline CAC score was a significant predictor of mortality after adjustment for age, race, gender, and diabetes with increased mortality proportional to baseline score with greater risk of death for patients treated with calcium-containing phosphate binders persisted after full multivariable adjustment.
References
More filters
Journal Article

Protein Measurement with the Folin Phenol Reagent

TL;DR: Procedures are described for measuring protein in solution or after precipitation with acids or other agents, and for the determination of as little as 0.2 gamma of protein.
Journal ArticleDOI

Coronary-Artery Calcification in Young Adults with End-Stage Renal Disease Who Are Undergoing Dialysis

TL;DR: Coronary-artery calcification is common and progressive in young adults with end-stage renal disease who are undergoing dialysis who are undergoing dialysis.
Journal ArticleDOI

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study

TL;DR: This study concludes that a large percentage of hemodialysis patients who have a serum phosphorus level above 6.5 mg/dL and that this places them at increased risk of death, and supports the need for vigorous control of hyperphosphatemia to improve patient survival.

Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis

TL;DR: In this paper, the authors used electron-beam computed tomography (CT) to screen for coronary-artery calcification in 39 young patients with end-stage renal disease who were undergoing dialysis (mean [±SD] age, 19±7 years; range, 7 to 30).
Journal ArticleDOI

Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein

TL;DR: Mgp, a mineral-binding ECM protein3 synthesized by vascular smooth-muscle cells and chondrocytes, is the first inhibitor of calcification of arteries and cartilage to be characterized in vivo.
Related Papers (5)